New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
07:06 EDTAGEN, BMYAgenus initiates Prophage Phase 2 trial
Agenus (AGEN) announced initiation of a randomized Phase 2 trial with Prophage for melanoma, and Bristol-Myers Squibb's (BMY) Yervoy for the treatment of Stage III and IV metastatic melanoma. The combination has the potential to trigger a more effective immune response against the tumor than Yervoy alone. The Phase 2, randomized, open label, single-center, investigator-sponsored trial is designed to evaluate the safety, feasibility and immunogenicity of the combination of Prophage vaccine and Yervoy with or without low dose cyclophosphamide in 25 patients with unresectable Stage III or IV metastatic melanoma. Jorge Quesada, principal investigator of the study said "The combination may improve the prospects for patients who do not respond to ipilimumab alone, which is approximately 70% of the metastatic melanoma patients."
News For AGEN;BMY From The Last 14 Days
Check below for free stories on AGEN;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
September 8, 2014
07:18 EDTAGENRodman & Renshaw to hold a conference
Subscribe for More Information
September 5, 2014
16:45 EDTBMYMarket ends week little changed after mixed economic data
Subscribe for More Information
11:17 EDTBMYBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
September 4, 2014
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use